LAG-3 (human) monoclonal antibody (17B4) (FITC conjugate)

The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses.

This antibody is covered by our Worry-Free Guarantee.

Citations: 27

View Online »

Ordering Information

Order Online »

ALX-804-806F-C100

FITC - 100µg

Manuals, SDS & CofA

View Online »




Figure: LAG-3 expression on activated human peripheral blood mononuclear cells (PBMC) detected with LAG-3 (human), mAb (17B4) (FITC) (Prod. No. ALX-804-806F). **Method:** T lymphocytes from human PBMC are stimulated with 1μg/ml of PHA for three days. Then, after seven days of culture, 3×10⁶ three-days PHA-activated human PBMC are treated with LAG-3 (human), mAb (17B4) (FITC) (Prod. No. ALX-804-806F) or FITC coupled isotype-matched (IgG1) control MAb (used at a saturating dilution of 1/800 and 1/150 respectively) for 30 min. at 4°C in RPMI 1640 and washed twice with 1x PBS. Stained cells are then analysed by FACS [4].




Figure: Expression of LAG-3 on CD4⁺ and CD8⁺ subpopulations of tumour infiltrating lymphocytes (TILs) detected with LAG-3 (human), mAb (17B4) (FITC) (Prod. No. ALX-804-806F). Method: TILs from a dissociated renal cell carcinoma sample, stained with 5µg/ml LAG-3 (human), mAb (17B4) (FITC) (Prod. No. ALX-804-806F) and FITC-coupled anti-CD4 or -CD8, are analyzed by a two-colour FACS analysis. Additional staining with anti-CD3 allowed a gate analysis of total T cells. Values indicate percentages in each quadrant [5].




Figure: Specific inhibition of 17B4 staining. **Method:** LAG-3 (human), mAb (17B4) (FITC) (Prod. No. ALX-804-806F) (10μg/ml) (is preincubated with a specific peptide epitope (208b) or a control tetanus toxoid (TT) peptide at different molarities prior to staining of TILs. Stained cells are then analyzed by FACS.




Figure: Tumor infiltrating lymphocytes (TILs) express LAG-3 (detected using LAG-3 (human), mAb (17B4) (Prod. No. ALX-804-806)). **Method:** Freshly dissociated single cell suspensions of renal cell carcinoma TILs are incubated with LAG-3 (human), mAb (17B4) (FITC) (Prod. No. ALX-804-806) (5μg/ml) and anti-MHC Class II molecules (PE) for 30 min. and washed twice in saline buffer. Additional staining with anti-CD3 allowed a gate analysis of total T cells. The LAG-3 and MHC II profiles of CD3⁺-gated cells for 3 patients are shown [5].

Handling & Storage

Use/Stability Stable for at least 6 months after receipt when stored as recommended.

Handling Do not freeze. Protect from light.

Short Term Storage +4°C

Long Term Storage +4°C

Shipping Blue Ice

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name Lymphocyte activation gene-3, FDC protein, CD223

Application Flow Cytometry

Application Notes Excellent for Flow Cytometry.

Clone 17B4

Formulation Liquid. In PBS containing 50mM Tris-HCl, 1% BSA and

0.02% sodium azide.

Host Mouse

Immunogen Synthetic peptide corresponding to 30 aa

(GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte

activation gene-3).

lgG1

Purity Detail Purified from concentrated hybridoma tissue culture

supernatant by Protein A Sepharose™ CL-4B Flow Fast

Column.

Source Purified from hybridoma tissue culture supernatant.

Species Reactivity Human

Specificity

Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3.

Technical Info / Product Notes

SEPHAROSE is a trademark of GE Healthcare companies.

UniProt ID

P18627

Worry-free Guarantee

This antibody is covered by our Worry-Free Guarantee

Last modified: May 29, 2024



info-

European Sales Office ENZO LIFE SCIENCES, ENZO LIFE SCIENCES Phone: 800.942.0430 (ELS) AG Phone: +41 61 926 8989 usa@enzolifesciences.com eu@enzolifesciences.com Belgium, The Netherlands & Luxembourg Phone: +32 3 466 0420 infobe@enzolifesciences.com

Phone: +33 472 440 655 fr@enzolifesciences.com

Phone: +49 7621 5500 526 de@enzolifesciences.com

UK & Ireland Phone (UK customers): 0845 601 1488 Phone: +44 1392 825900 uk@enzolifesciences.com